- Home
- MHK vs JAZZ Comparison
MHK vs JAZZ Comparison
Compare MHK & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHK
- JAZZ
- Stock Information
- Founded
- MHK 1988
- JAZZ 2003
- Country
- MHK United States
- JAZZ Ireland
- Employees
- MHK N/A
- JAZZ N/A
- Industry
- MHK Home Furnishings
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- MHK Consumer Discretionary
- JAZZ Health Care
- Exchange
- MHK Nasdaq
- JAZZ Nasdaq
- Market Cap
- MHK 7.2B
- JAZZ 6.1B
- IPO Year
- MHK 1992
- JAZZ 2007
- Fundamental
- Price
- MHK $106.25
- JAZZ $97.78
- Analyst Decision
- MHK Buy
- JAZZ Strong Buy
- Analyst Count
- MHK 14
- JAZZ 13
- Target Price
- MHK $141.64
- JAZZ $181.85
- AVG Volume (30 Days)
- MHK 751.0K
- JAZZ 1.3M
- Earning Date
- MHK 05-01-2025
- JAZZ 05-06-2025
- Dividend Yield
- MHK N/A
- JAZZ N/A
- EPS Growth
- MHK N/A
- JAZZ 49.21
- EPS
- MHK 7.66
- JAZZ 7.51
- Revenue
- MHK $10,683,300,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- MHK $0.06
- JAZZ $7.60
- Revenue Next Year
- MHK $3.07
- JAZZ $3.47
- P/E Ratio
- MHK $13.88
- JAZZ $13.00
- Revenue Growth
- MHK N/A
- JAZZ 5.76
- 52 Week Low
- MHK $96.24
- JAZZ $95.49
- 52 Week High
- MHK $164.29
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- MHK 50.29
- JAZZ 33.01
- Support Level
- MHK $99.90
- JAZZ $97.50
- Resistance Level
- MHK $107.68
- JAZZ $120.67
- Average True Range (ATR)
- MHK 3.27
- JAZZ 4.33
- MACD
- MHK 0.35
- JAZZ -0.53
- Stochastic Oscillator
- MHK 63.56
- JAZZ 1.21
About MHK Mohawk Industries Inc.
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.